Affiliation:
1. Pharmacology & Toxicology Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
Abstract
Objective:
This study aimed to investigate the effect of atorvastatin on daclatasvir oral pharmacokinetics
and safety and assess the possible underlining mechanisms by targeting P-glycoprotein (P-gp) and cytochrome P450
(CYP3A4).
Methods:
The transport of daclatasvir, as well as the standard rhodamine 123 by P-gp across the rat intestine, was
studied in vitro using the non-everted sac method. To assess the pharmacokinetic profile of daclatasvir in vivo, rats
were divided into three groups receiving either saline, standard P-gp inhibitor verapamil (25 mg/kg), or atorvastatin
(10 mg/kg), 2 hrs prior to a single dose of daclatasvir (7 mg/kg). In addition, the markers of liver and kidney functions
and muscle rhabdomyolysis were assessed. Further, histopathological examination of liver and kidney tissue
and assessment of CYP3A4 level was done.
Results:
The inhibitory effect of atorvastatin on Pgp activity and expression was manifested by increased serosal
transport of the standard rhodamine 123, as well as daclatasvir. In vivo, Cmax (peak plasma concentration) and area
under the curve (AUC (0‐t)) of daclatasvir after atorvastatin treatment increased compared to the vehicle group but
not in a significant manner. On the other hand, atorvastatin caused a significant increase in the clearance of daclatasvir.
Concomitant administration of atorvastatin with daclatasvir significantly decreased CYP3A4 content compared
to the control group. The combination also showed increased liver enzymes and some pathological alterations in the
liver.
Conclusion:
Atorvastatin has a significant effect on P-gp mediated intestinal transport of daclatasvir; however, it did
not affect the systemic bioavailability of a single oral dose of daclatasvir.
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Pharmacology
Reference12 articles.
1. Jayaraman R.; Pasha M.K.; Williams A.; Goh K.C.; Ethirajulu K.;
2015. Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans. Drug Metab Lett Jan 18 [Epub ahead of print].
2. Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K; 2011. Preclinical
metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug
Metab Dispos ,Dec 39(12),2219-32
3. Ethirajulu Kantharaj and Ramesh Jayaraman. 2011. Histone deacetylase inhibitors as therapeutic agents for cancer therapy: Drug Metabolism and pharmacokinetic
properties Chapter 5 "Drug Development - A Case Study Based Insight into Modern Strategies", book edited by Chris Rundfeldt, ISBN
978-953-307-257-9, Published: December 7, 2011 under CC BY 30 license 2011
4. Younes A.; Romaguera J.; Fanale M.; McLaughlin P.; Hagemeister F.; Copeland A.; Neelapu S.; Kwak L.; Shah J.; de Castro Faria S.; Hart S.; Wood J.; Jayaraman R.; Ethirajulu K.; Zhu J.; 2012. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol ,30(33),4161-4167
5. Madan B.; Goh K.C.; Hart S.; William A.D.; Jayaraman R.; Ethirajulu K.; Dymock B.W.; Wood J.M.; 2012. SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis. J Immunol ,189(8),4123-4134
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献